Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its…
Luzitin, Portugal
Last updated: 13.02.2014
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Interviews
Related
Medical Use of Cannabis in Portugal: Current Status and Perspectives
Lawyer Joana Silveira Botelho provides regular legal assistance to pharmaceutical companies and other entities of…
Santiago Ruiz – Director General, B. Braun Portugal
Santiago Ruiz, entering his fourth year leading B. Braun’s Portuguese affiliate in Lisbon, highlights the…
Joaquim Chaves, CEO, Basi Laboratories, Portugal
Joaquim Chaves, CEO of Basi Laboratories, presents the Basi production success story to readers. Located in…
Francisco del Val, Country Manager, Sanofi Portugal
Francisco del Val, recently nominated general manager of the business unit Sanofi Genzyme and country head of…
Virgilio Bento CEO, SWORD Health, Portugal
Virgilio Bento, known as ‘V’ amongst his peers, invites readers to discover SWORD Health, an interactive…
Portugal’s Potential as a Pharma Testing Ground
Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a…
Bruno Soares – CEO, Coimbra Genomics, Portugal
Coimbra Genomics aims to make genetics easier. The company has developed Elsie, a digital platform that helps make…
Interview: Maria Queiroz – Founder and CEO, Eurotrials, Portugal
Eurotrials is a full-service contract research organization (CRO) with an international footprint in over five…
Interview: João Norte – CEO, HMR, Portugal
Health Market Research (HMR) is a multinational healthcare knowledge generation company, with origins in Portugal…
Interview: Filipe Novais – General Manager, Astellas Portugal
Filipe Novais leads the Portuguese affiliate for Astellas during an exciting time for the company globally. With a…
Interview: Jorge Sequeira – Country Manager, Cerner Portugal
Jorge Sequeira, general manager for Cerner Portugal, sheds light on Portuguese prowess in healthcare technology.…
Interview: Mario Maderia – General Manager, Teva Portugal
Mario Madeira, general manager of Teva Portugal, highlights the milestones of the affiliate in Portugal,…
